The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 14, 2026

Filed:

Jul. 19, 2022
Applicant:

Astrazeneca Ab, Södertälje, SE;

Inventors:

Sten Nilsson-Lill, Södertälje, SE;

Kathryn Giblin, Cambridge, GB;

Frederick Woolf Goldberg, Cambridge, GB;

Jason Grant Kettle, Cambridge, GB;

Amber Balazs, Gaithersburg, MD (US);

Randolph Escobar, Gaithersburg, MD (US);

Tyler Grebe, Gaithersburg, MD (US);

Neil Patrick Grimster, Gaithersburg, MD (US);

Anthony Metrano, Gaithersburg, MD (US);

Adelphe Mfuh, Gaithersburg, MD (US);

Lucas Morrill, Gaithersburg, MD (US);

Li Sha, Gaithersburg, MD (US);

James Sheppeck, Gaithersburg, MD (US);

Jason Shields, Gaithersburg, MD (US);

Kun Song, Gaithersburg, MD (US);

Dedong Wu, Gaithersburg, MD (US);

Ye Wu, Gaithersburg, MD (US);

Robert Evans Ziegler, Gaithersburg, MD (US);

Assignee:

ASTRAZENECA AB, Södertälje, SE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5377 (2006.01); A61K 31/497 (2006.01); A61K 31/541 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 31/497 (2013.01); A61K 31/541 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract

There are disclosed certain substituted pyrazine-2-carboxamides of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of hematopoietic progenitor kinase 1 (HPK1) and are thereby particularly useful in the treatment or prophylaxis of cancer.


Find Patent Forward Citations

Loading…